Insulet PODD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.71B+30.7% | $2.07B+22.1% | $1.7B+30.0% | $1.31B+18.8% | ||
| $768.2M+22.7% | $625.9M+16.5% | $537.2M+7.5% | $499.7M+44.1% | ||
| $1.94B+34.2% | $1.45B+24.6% | $1.16B+44.0% | $805.6M+7.1% | ||
| 71.6%+1.8pp | 69.8%+1.4pp | 68.3%+6.6pp | 61.7%-6.7pp | ||
| $301.1M+37.1% | $219.6M+7.1% | $205M+13.8% | $180.2M+12.6% | ||
| $1.17B+27.0% | $917.2M+24.8% | $734.8M+25.0% | $587.8M+26.1% | ||
| —— | —— | —— | —— | ||
| $90.4M+11.9% | $80.8M+11.0% | $72.8M+15.2% | $63.2M+10.1% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $473.9M+53.5% | $308.8M+40.3% | $220.1M+485% | $37.6M-70.2% | ||
| 17.5%+2.6pp | 14.9%+1.9pp | 13%+10.1pp | 2.9%-8.6pp | ||
| $59.3M+38.9% | $42.7M+18.0% | $36.2M— | —— | ||
| $34.7M-12.2% | $39.5M+38.1% | $28.6M— | —— | ||
| $14.3M+342% | -$5.9M-368% | $2.2M— | —— | ||
| -$123.9M— | $0— | $0— | $0+100% | ||
| $339.6M+13.1% | $300.3M+39.9% | $214.7M+2,091% | $9.8M-52.2% | ||
| $92.3M+172% | -$128.7M-1,651% | $8.3M+59.6% | $5.2M+40.5% | ||
| $247.1M-40.9% | $418.3M+103% | $206.3M+4,385% | $4.6M-72.6% | ||
| 9.1%-11.1pp | 20.2%+8.0pp | 12.2%+11.8pp | 0.4%-1.2pp | ||
| $3.49-39.6% | $5.78+96.6% | $2.94+4,100% | $0.07-69.6% | ||
| $3.50-41.5% | $5.98+103% | $2.95+4,114% | $0.07-70.8% | ||
| 287.3M-2.7% | 295.4M+2.7% | 287.5M+3.2% | 278.5M+2.8% | ||
| 281.4M+0.4% | 280.2M+0.5% | 278.9M+0.5% | 277.4M+3.0% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $6.2M-15.1% | $7.3M+9.0% | $6.7M+15.5% | $5.8M-85.6% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $62.2M— | —— | —— | -$1M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$11M-358% | -$2.4M+84.6% | ||
| —— | —— | —— | $133.9M+490% | ||
| —— | —— | —— | $49.1M-68.2% | ||
| $81.7M+273% | $21.9M-49.1% | $43M+16.8% | $36.8M-21.2% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$595.3M— | —— | —— | -$40.3M-195% | ||
| -$222.7M-52.3% | -$146.2M-22.4% | -$119.4M+37.5% | -$191.1M-131% | ||
| $569.3M+32.3% | $430.2M+195% | $145.7M+22.4% | $119M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $14.3M+342% | -$5.9M-368% | $2.2M— | —— | ||
| $7M+42.9% | $4.9M— | —— | $3.8M— | ||
| $59.6M— | —— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $25.9M+241% | $7.6M-42.4% | $13.2M-21.4% | $16.8M-40.4% | ||
| $191.6M+53.4% | $124.9M+65.2% | $75.6M-38.5% | $122.9M+9.8% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $19M+132% | $8.2M-49.7% | $16.3M+136% | $6.9M-55.2% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | -$300K-113% | $2.3M-45.2% | $4.2M+35.5% | ||
| —— | —— | —— | —— | ||
| $1.05B— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $62.7M-9.5% | $69.3M+43.2% | $48.4M+18.3% | $40.9M+18.9% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $473.9M+53.5% | $308.8M+40.3% | $220.1M+485% | $37.6M-70.2% | ||
| $564.3M+44.8% | $389.6M+33.0% | $292.9M+191% | $100.8M-45.0% | ||
| $564.3M+44.8% | $389.6M+33.0% | $292.9M+191% | $100.8M-45.0% | ||
| 20.8%+2.0pp | 18.8%+1.5pp | 17.3%+9.5pp | 7.7%-9.0pp | ||
| $473.9M+53.5% | $308.8M+40.3% | $220.1M+485% | $37.6M-70.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insulet's revenue?
- Insulet (PODD) generated $2.9B in revenue over the trailing twelve months, up 31.9% year over year.
- Is Insulet profitable?
- Insulet reported $302.8M in net income over the trailing twelve months, a 10.4% net margin.
- What are Insulet's profit margins?
- Gross margin is 71.0% and operating margin is 17.5%, with a 10.4% net margin.
- What is Insulet's earnings per share?
- Insulet's diluted EPS over the trailing twelve months is $4.29.
- Where does Insulet's income statement data come from?
- Every line is extracted from Insulet's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
